Compare Stille AB with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
SEK 1,528 Million (Small Cap)
34.00
NA
0.00%
-0.20
5.91%
2.21
Revenue and Profits:
Net Sales:
125 Million
(Quarterly Results - Jun 2025)
Net Profit:
10 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-14.04%
0%
-14.04%
6 Months
-34.78%
0%
-34.78%
1 Year
-35.9%
0%
-35.9%
2 Years
3.81%
0%
3.81%
3 Years
26.58%
0%
26.58%
4 Years
13.21%
0%
13.21%
5 Years
68.54%
0%
68.54%
Stille AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
31.89%
EBIT Growth (5y)
41.13%
EBIT to Interest (avg)
9.03
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.22
Sales to Capital Employed (avg)
0.82
Tax Ratio
18.46%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
17.21%
ROE (avg)
9.60%
Valuation key factors
Factor
Value
P/E Ratio
34
Industry P/E
Price to Book Value
2.54
EV to EBIT
23.59
EV to EBITDA
17.86
EV to Capital Employed
3.02
EV to Sales
2.98
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
12.79%
ROE (Latest)
7.46%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
124.70
129.30
-3.56%
Operating Profit (PBDIT) excl Other Income
24.90
24.80
0.40%
Interest
0.00
4.80
-100.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
10.00
14.60
-31.51%
Operating Profit Margin (Excl OI)
137.10%
135.70%
0.14%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is -3.56% vs -19.09% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -31.51% vs -2.67% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
570.00
294.90
93.29%
Operating Profit (PBDIT) excl Other Income
136.50
62.00
120.16%
Interest
5.00
10.10
-50.50%
Exceptional Items
-24.10
0.00
Consolidate Net Profit
58.20
26.60
118.80%
Operating Profit Margin (Excl OI)
161.00%
161.70%
-0.07%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 93.29% vs 19.73% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 118.80% vs -2.56% in Dec 2023
About Stille AB 
Stille AB
Pharmaceuticals & Biotechnology
Stille AB is a Sweden-based company engaged in the development, manufacture, and marketing of technical medical equipment. The product portfolio is divided into two business lines. The Surgery business area develops, produces and markets handcrafted, forged surgical instruments for all fields of open surgery, with an emphasis on cardiovascular surgery, and reconstructive and aesthetic plastic surgery. Its products include scissors, forceps, artery forceps, needle holders and clamps, among others. The Patient Positioning area develops and manufactures two main groups of procedure-specific specialized tables for cardiovascular surgery and gynecology, urology and urodynamic examinations. As of December 31, 2011, the Company had two wholly owned subsidiaries, Stille Surgical Inc. and Stille Incentive AB. As of December 30, 2011, the it's largest shareholder was Linc Invest AB (39.81%). On September 2, 2013, the Company sold its business unit, Sonesta, to ADDvise Lab Solutions publ AB.
Company Coordinates 
Company Details
Ekbacken 11 , TORSHAELLA None : 644 30
Registrar Details






